ZURA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 8.72%, SMA50 21.66%, SMA200 114.89%). The stock’s 14-day RSI is 62.37 (firm momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.84% below its high and over 597.94% above its low. Average 10-day trading volume of 628.02 thousand shares is in line with the 3-month average of 593.32 thousand, indicating normal recent market interest.

Zura Bio Limited has 65.02 million shares outstanding. The public float is 37.88 million shares, elevated short interest at 0.72% of float. This equals 425.34 thousand shares. The short ratio is 1.15 days. Institutional investors hold 99.67% of the float. Insiders own 29.16%. AI Biotechnology LLC holds 6.55 million shares, Sidhu Someit has 2.09 million shares and Munshi Amit has 777.38 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Wall Street analysts project EPS growth of -3.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $2.00. The high target offers 268.1% upside. The low target suggests -59.1% downside. The mean target is $11.89. This offers 143.15% upside. Zura Bio Limited earnings surprise history is a mixed track record. The quarter that ended March 19, 2026, missed forecasts by 172.22%. The prior quarter beat by 11.52%. Over the last six quarters, Apple has recorded several small beats. These include 85.71% in November 07, 2024.

Zura Bio Limited (NASDAQ:ZURA) closed at $4.89 USD, losing -$0.29 (-5.60%) from the previous close of $5.18. The stock is currently mid-range between its 52-week high and low $0.98 and $7.44. With a market capitalization of about $317.96 million, Zura Bio Limited is classified as a small-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 591.35 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Zura Bio Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sandeep C. Kulkarni, the company employs approximately 30 people and listed since March 21, 2023. Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.

Zura Bio Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.16. This means the shares are trading above this model’s fair value.

Zura Bio Limited trades at a P/E ratio of -4.69, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.59 trading at moderately above to book value. The P/FCF stands at -4.96, also above market averages.

Zura Bio Limited (NASDAQ:ZURA) shares are flat -4.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zura Bio Limited trading at a premium to the broader market with a P/E of -4.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.88, suggesting 142.94% upside. Our AI forecast model points to short-term weakness (-3.07% over two weeks), a medium-term fall (-40.08% over three months), and a longer-term gain (440.08% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zura Bio Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.07%, with price expected at $4.74 by May 20, 2026, within a range of $4.44 to $5.07 3-Month Outlook: Projected fall of -40.08%, reaching $2.93 by August 04, 2026, with a range of $2.77 to $3.10. 1-Year Outlook: Projected gain of 440.08%, with price at $26.41 by May 06, 2027, within a range of $26.38 to $28.24.